{"editorial":{"content_id":"66b00a22-55ab-45dd-9cc6-2dfcf208534a","slug":"ans-20261118-7a1ab6","content_type":"news","title":"巴西ANS将肺癌基因检测与靶向药纳入医保强制覆盖，2027年2月生效","summary":"巴西国家补充健康局（ANS）发布新决议，将肺癌新一代测序检测和口服药甲磺酸特普替尼纳入健康保险计划强制覆盖清单，2027年2月生效。","body":"巴西国家补充健康局（ANS）发布新决议，将肺癌治疗相关的检查与药物纳入健康保险计划的强制覆盖程序清单。患者将有权获得新一代测序方案以及口服药物甲磺酸特普替尼（cloridrato de tepotinibe）。根据联邦官方公报公布的内容，新覆盖范围将于2027年2月生效。\n\nANS表示，此次更新覆盖清单旨在扩大精准医学技术的可及性，使相关基因变异得以识别，从而支持特定疗法的实施。\n\n据规定，肺癌新一代测序（NGS）面板用于识别与该疾病相关的基因组变异。该检测的强制覆盖适用于非鳞状非小细胞肺癌、处于晚期或转移阶段（IIIB至IV期）的患者，需识别EGFR、ALK、ROS1、RET、NTRK、BRAF、MET、KRAS和HER2基因的变异。分析应优先使用肿瘤组织样本；在材料不足的情况下，可通过液体活检使用血液样本。\n\n甲磺酸特普替尼则面向携带MET基因第14外显子跳跃突变（METex14）的晚期非小细胞肺癌成年患者。\n\nANS称，此次纳入遵循第9.656/1998号法律的规定，该法律涉及私人健康保险计划与保险。（信息来自巴西通讯社）","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","行业趋势","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-18T23:04:52.719Z","display_date":"2026-11-18","source_published_at":null,"source_url":"https://medicinasa.com.br/ans-cobertura-cancer/","source_name":"Medicina S/A","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":["regulatory_uncertainty","compliance_risk"],"opportunity_flags":["market_entry_opportunity","investment_signal","partnership_opportunity"],"trend_signals":["precision_medicine_adoption","healthcare_coverage_expansion"]},"intelligence":{"intel_id":"fe8d3694-0075-427d-8568-2d7bfb783a6f","version":1,"event_type":"政策发布","event_date":null,"main_entities":[{"name":"巴西国家补充健康局（ANS）","role":"发布新决议并将肺癌NGS检测与甲磺酸特普替尼纳入健康保险强制覆盖清单","type":"regulator","country":"巴西","normalized_name":null},{"name":"甲磺酸特普替尼（cloridrato de tepotinibe）","role":"被纳入强制覆盖的口服靶向药物","type":"product","country":"其他","normalized_name":null},{"name":"肺癌新一代测序（NGS）面板","role":"被纳入强制覆盖的肺癌基因检测方案","type":"product","country":"其他","normalized_name":null},{"name":"第9.656/1998号法律","role":"私人健康保险计划覆盖义务的法律依据","type":"policy","country":"巴西","normalized_name":null}],"main_action":"ANS将肺癌NGS检测与特普替尼纳入巴西医保强制覆盖清单","key_numbers":[{"unit":"年","label":"生效年份","value":"2027"},{"unit":"月","label":"生效月份","value":"2"},{"unit":"个","label":"NGS覆盖基因数量","value":"9"},{"unit":"期","label":"NGS适用分期","value":"IIIB-IV"}],"facts":[{"verified":false,"statement":"巴西国家补充健康局（ANS）发布新决议，将肺癌治疗相关的检查与药物纳入健康保险计划的强制覆盖程序清单。","source_excerpt":null},{"verified":false,"statement":"新覆盖范围包括肺癌新一代测序（NGS）方案和口服药物甲磺酸特普替尼（cloridrato de tepotinibe），将于2027年2月生效。","source_excerpt":null},{"verified":false,"statement":"肺癌NGS检测的强制覆盖适用于非鳞状非小细胞肺癌、处于晚期或转移阶段（IIIB至IV期）的患者，需识别EGFR、ALK、ROS1、RET、NTRK、BRAF、MET、KRAS和HER2基因的变异。","source_excerpt":null},{"verified":false,"statement":"NGS分析应优先使用肿瘤组织样本；在材料不足的情况下，可通过液体活检使用血液样本。","source_excerpt":null},{"verified":false,"statement":"甲磺酸特普替尼面向携带MET基因第14外显子跳跃突变（METex14）的晚期非小细胞肺癌成年患者。","source_excerpt":null},{"verified":false,"statement":"ANS称此次纳入遵循第9.656/1998号法律的规定，该法律涉及私人健康保险计划与保险。","source_excerpt":null}],"assessments":[{"statement":"该政策扩大精准医学在巴西私人健康保险中的强制可及性，对NGS检测和MET靶向药相关企业构成市场机会。","confidence":"high","basis_fact_index":null},{"statement":"由于新覆盖范围2027年2月才生效，保险计划、检测网络和药物供应需提前准备，执行细则仍待明确。","confidence":"medium","basis_fact_index":null},{"statement":"覆盖范围限定特定患者群体和基因列表，实际影响取决于医生检测路径、保险授权流程和检测可及性。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"追踪ANS新决议编号、全文及2027年2月生效前的执行细则。"},{"target":"user","priority":"normal","description":"评估NGS检测与甲磺酸特普替尼在巴西私人医保市场的准入、定价和报销流程。"},{"target":"both","priority":"normal","description":"关注甲磺酸特普替尼在巴西的ANVISA注册状态及检测实验室资质要求。"}],"affected_audience":["非鳞状非小细胞肺癌晚期或转移患者","携带METex14的晚期非小细胞肺癌成年患者","巴西私人健康保险受益人","NGS检测服务提供商","肺癌靶向药相关企业"],"risk_flags":["regulatory_uncertainty","compliance_risk"],"opportunity_flags":["market_entry_opportunity","investment_signal","partnership_opportunity"],"trend_signals":["precision_medicine_adoption","healthcare_coverage_expansion"],"follow_up_needed":true,"follow_up_questions":["ANS新决议的编号和全文在哪里可查？","强制覆盖是否适用于所有个人和集体健康保险计划？","甲磺酸特普替尼在巴西的ANVISA注册和定价状态如何？","NGS检测的实验室资质、报销编码和授权流程是否已明确？"],"related_topics":["巴西ANS","肺癌","NGS检测","甲磺酸特普替尼","METex14","医保强制覆盖","精准医疗"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-11-18T23:05:24.368Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/ans-20261118-7a1ab6","api_url":"https://chinabrazilinsight.com/api/public/content/ans-20261118-7a1ab6","markdown_url":"https://chinabrazilinsight.com/api/public/content/ans-20261118-7a1ab6?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/ans-20261118-7a1ab6?view=json","last_updated":"2026-11-18T23:05:24.474Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}